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Objectives
To study the measurement properties of a joint specific patient reported outcome measure, 
a measure of capability and a general health-related quality of life (HRQOL) tool in a large 
cohort of patients with a hip fracture.
Methods
Responsiveness and associations between the Oxford Hip Score (a hip specific measure: 
OHS), ICEpop CAPability (a measure of capability in older people: ICECAP-O) and EuroQol 
EQ-5D (general health-related quality of life measure: EQ-5D) were assessed using data 
available from two large prospective studies. The three outcome measures were assessed 
concurrently at a number of fixed follow-up time-points in a consecutive sequence of 
patients, allowing direct assessment of change from baseline, inter-measure associations 
and validity using a range of statistical methods.
Results
ICECAP-O was not responsive to change. EQ-5D was responsive to change from baseline, 
with an estimated standardised effect size for the two datasets of 0.676 and 0.644 at 
six weeks and four weeks respectively; this was almost as responsive to change as OHS 
(1.14 at four weeks). EQ-5D correlated strongly with OHS; Pearson correlation 
coefficients were 0.74, 0.77 and 0.70 at baseline, four weeks and four months. EQ-5D is a 
moderately good predictor of death at 12 months following hip fracture. Furthermore, 
EQ-5D reported by proxies (relatives and carers) behaves similarly to self-reported 
scores.
Conclusions
Our findings suggest that a general HRQOL tool such as EQ-5D could be used to measure 
outcome for patients recovering from hip fracture, including those with cognitive 
impairment.
Cite this article: Bone Joint Res 2014;3:69–75.
Article focus
 The measurement properties and
association between the Oxford Hip Score,
ICECAP-O and EuroQol EQ-5D in a large
cohort of patients with a hip fracture
Key messages
 Our findings suggest that a general health-
related quality of life tool such as EQ-5D has
good measurement properties and could
feasibly be used as an outcome measure for
patients recovering from hip fracture
Strengths and limitations
 This is a large study that reports strong
and highly significant associations
between hip specific function and gen-
eral quality of life outcome measures in
patients after hip fracture 
 The main limitation is the fact that all of
the data were collected in a single
trauma centre; further research is
required to see whether EQ-5D is
feasible and generalisable for other UK
centres.
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Introduction
Fragility fracture of the proximal femur (hip fracture) is
one of the biggest healthcare challenges of the twenty-
first century. In 1990 the global incidence of hip fractures
was 1.31 million and was associated with 740 000
deaths.1 With an ageing population, the morbidity, mor-
tality and socioeconomic costs of hip fracture have
increased substantially.2
Traditionally, outcome after hip fracture has been mea-
sured using characteristics such as mortality, the need for
further surgery and length of patient stay in hospital. This
focus on mortality and ‘process’ data is reflected in the
outcomes reported in the UK National Hip Fracture Data-
base (NHFD).3 However, it is increasingly recognised and
expected that healthcare evaluations should routinely
include health domains that are important to patients;
patient reported outcome measures (PROMs) aim to
assess how patients function and feel about their condi-
tion and the success or otherwise of their treatment.4,5
For patients who have sustained a hip fracture, there is
little consensus on the most appropriate PROM.6,7 In
many areas of healthcare, PROMs specific to a particular
disease or area of the body are considered the most sen-
sitive to changes in outcome. However, patients who suf-
fer fragility fracture of the hip represent a highly
heterogeneous population; ranging from extremely frail
to fit and active patients, with and without serious
comorbidities or cognitive impairment, sometimes with
pre-existing deterioration in health-related quality of life
(HRQOL). Therefore, it may be that we need to think
unconventionally about appropriate outcome measures
in this population.
We compared the measurement properties of a joint
specific PROM – Oxford Hip Score (OHS),8 a measure of
capability in older people – ICEpop CAPability measure
for older people (ICECAP-O)9 and a general HRQOL tool –
EuroQol EQ-5D (EQ-5D)10 in a large cohort of patients
with a hip fracture.
Methods
Data. Data were available from two distinct, but related,
studies.
The Warwick Hip Trauma (WHiT) study11 was a single
centre, parallel group randomised controlled trial.
Between September 2009 and April 2011, 225 partici-
pants aged 65 years and over with an intracapsular frac-
ture of the hip were recruited. All participants were
followed-up at six weeks, 12 weeks and one year post-
operatively and completed the EQ-5D at each time-point.
In addition, basic demographic data were recorded on
admission (baseline), and trial participants were asked
retrospectively to report score data to assess function and
quality of life before the fracture. Full details of the study
and treatment effects are described in detail elsewhere.12
The Warwick Hip Trauma Evaluation (WHiTE) study13 is
a prospective cohort study performed at the same trauma
centre, in an analogous manner and as an immediate
extension of the WHiT study. Recruitment began in Janu-
ary 2012, and is on-going, with data currently available
from 249 participants, all aged 60 years and above with
all types of hip fractures. Following consent, all partici-
pants report their pre-operative hip function (OHS),
quality of life (EQ-5D) and capability (ICECAP-O) retro-
spectively assessed through questionnaires. This is fol-
lowed by telephone questionnaires at four weeks, four
months and 12 months post-operatively. For those partic-
ipants with cognitive impairment (defined as an abbrevi-
ated mental test (AMT) score less than 8),14 this
assessment is limited to the EQ-5D, which is reported by
an appropriate proxy.
Outcomes. EQ-5D is a validated, generalised and stan-
dardised instrument comprising a visual analogue scale
(VAS) measuring self-rated health and a health status
instrument, consisting of a three-level response (no prob-
lems, some problems and extreme problems) for five
domains related to daily activities10; (i) mobility, (ii) self-
care, (iii) usual activities, (iv) pain and discomfort and
(v) anxiety and depression. Responses to the health status
classification system are converted into an overall score
using a published utility algorithm for the UK popula-
tion.15 A respondent’s EQ-VAS gives self-rated health on a
scale where the endpoints are labelled ‘best imaginable
health state’ (100) and ‘worst imaginable health state’ (0).
OHS was introduced in 1996 and uses 12 multiple
choice questions to quantify disability secondary to hip
osteoarthrosis.8 It has good evidence supporting its
validity8,16,17 and is entirely patient-reported, thus can be
administered by post or telephone as well as in the clini-
cal setting, without the need for an assessment by a clini-
cian. Each of the 12 items comprising the OHS is assessed
on a scale from zero to four, where zero represents, for
instance, no pain or difficulty in undertaking the task in
question. The scores for the 12 items are summed for
each patient to give an overall score that quantifies hip
function on a scale from 0 to 48, where 0 indicates excel-
lent hip function and 48 indicates very poor hip function.
ICECAP-O is a measure of capability in older people.9 It
comprises five attributes that are important to older people
in the UK; (i) attachment (love and friendship), (ii) security
(thinking about the future without concern), (iii) role
(doing things that make you feel valued), (iv) enjoyment
(enjoyment and pleasure) and (v) control (independence).
Each attribute is assessed using four ordered levels from the
lowest capability (level 1) to the highest capability (level 4),
and scaled using UK index values18 to ensure overall ICE-
CAP-O values were constrained between zero (no capac-
ity) and one (full capacity).
Statistical analysis. Descriptive data summaries (mean,
standard deviation [SD], median and range) were calcu-
lated at each occasion to assess overall population changes
and variability. Standardised effect sizes, calculated as the
difference in means between the index occasion and the
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baseline assessment divided by the baseline standard devi-
ation, were estimated in order to assess responsiveness for
all of the available outcome measures. Paired t-tests were
also calculated to assess the significance of changes in
mean outcome measures from baseline. For WHiT, receiver
operator characteristic (ROC) curves were constructed for
six weeks of EQ-5D using the defined gold-standard out-
comes of subsequent revision and death within
12 months. Areas under the curves, and 95% boot-
strapped confidence intervals, were calculated to assess
the predictive power of post-operative EQ-5D. Scatterplots
were used to assess ceiling and floor effects visually. Con-
struct validity was also assessed by scatterplot and by pair-
wise correlations between outcome measures, which were
quantified using Pearson’s correlation coefficient. This was
further explored for OHS and EQ-5D data, available from
WHiTE, by calculation of item-to-item Spearman correla-
tion coefficients; that is correlations between all pairs of
individual questionnaire items. Responsiveness was
quantified for proxy and patient scored EQ-5D for WHiTE
by calculating appropriate statistics for demented and
non-demented groups. EQ-5D and ICECAP-O data for this
population were compared with previously reported nor-
mative values for the UK population. Statistical significance
was set at the 5% level and all analyses were undertaken
using the statistical software package R.19
Results
Characteristics of the sample. Baseline characteristics for
WHiT participants are shown in Table I and summaries of
Table I. Baseline characteristics of WHiT study participants (n = 225)
Characteristic Measure
Mean SD
Age in years 83.1 (7.94)










Displaced fracture 48:177 (21%:78%)
Platelet drugs 160:64 (71%:29%)
NSAID§ 217:8 (96%:4%)
*F:M, Female:Male
†Percentages interpreted based on full population
‡N:Y, No:Yes
§NSAID, Non-steroidal anti-inflammatory drug
Table II. Summary of EQ-5D and EQ-VAS outcome data for WHiT at baseline
(Base), and six weeks (6w), 12 weeks (12w) and 52 weeks (52w) post-operation
Base 6w 12w 52w
EQ-5D
n 151 125 121 107
Range (-0.48 to 1) (-0.32 to 1) (-0.35 to 1) (-0.24 to 1)
Median 0.73 0.52 0.69 0.69
Mean 0.66 0.44 0.56 0.57
SD 0.32 0.32 0.31 0.34
Effect Size* - 0.68 0.32 0.27
t-test† - < 0.001 < 0.001 < 0.001
EQ-VAS
n 93 63 65 47
Range (10 to 100) (28 to 100) (1 to 100) (1 to 100)
Median 70.0 70.0 70.0 80.0
Mean 67.6 66.2 66.9 74.7
SD 19.3 18.7 21.4 20.8
Effect Size* - 0.07 0.03 -0.37
t-test† - 0.712 0.882 0.368
* Effect size, change in mean from baseline/baseline standard deviation (SD) 
† Paired t-test, comparison with baseline data
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outcome measures, EQ-5D and EQ VAS, in Table II. Table
II shows estimates of the means, medians and standard
deviations at baseline and each of the follow-up time
points at six weeks, 12 weeks and 52 weeks. Baseline char-
acteristics for WHiTE participants are shown in Table III and
summaries of outcome measures, OHS, EQ-5D, EQ VAS
and ICECAP-O, in Table IV. Table IV shows estimates of the
means, medians and standard deviations at baseline and
each of the follow-up time points at four weeks and four
months. Also shown are effect sizes, which are used to
assess responsiveness to change from baseline, and paired
t-tests at four weeks and four months.
Longitudinal change in outcome scores. There was clear
evidence from both WHiT and WHiTE of a smooth
increase in EQ-5D scores in the post-operative period, as
patients returned to comparatively normal function
(Table II and Table IV); that is scores gradually returned to
their pre-operative (baseline) level. 
The estimated (standardised) effect size in the WHiT
Study decreased from a medium to a small level during
follow-up for EQ-5D (0.68 at six weeks, 0.32 at 12 weeks
and 0.27 at 52 weeks), consistent with the change in
mean scores. EQ-VAS proved to be unresponsive to
change from baseline. ROC curves for six week EQ-5D
based on estimated sensitivity and specificity for subse-
quent revision and death within 12 months are shown in
Figure 1. The estimated area under the ROC curve (AUC)
Table III. Baseline characteristics of WHiTE participants
Characteristic* Total† (n = 249) Demented (n = 103) Non-demented (n = 139)
Age in years (mean and SD) 83.6 (7.77) 85.6 (6.37) 82.0 (8.28)
Sex (F:M) 180:60 (75%:25%) 78:21 (79%:21%) 100:39 (72%:28%)
Smoker (N:Y) 215:32 (87%:13%) 91:11 (89%:11%) 119:20 (86%:14%)
Diabetic (N:Y) 213:30 (88%:12%) 93:8 (92%:8%) 115:22 (84%:16%)
Chronic renal failure (N:Y) 233:8 (97%:3%) 97:2 (98%:2%) 132:5 (96%:4%)
*SD, standard deviation; F:M, Female:Male; N:Y, No:Yes
† Percentages interpreted based on full population
Table IV. Summary of (a) OHS, (b) EQ-5D, (c) EQ-VAS and (d) ICECAP-O outcome data for WHiTE at baseline (Base), and four weeks (4w) and four
months (4m)
Base 4w 4m Base 4w 4m
(a) OHS (b) EQ-5D
n 118 67 28 n 236 159 88
Range (11 to 48) (8 to 48) (19 to 48) Range (-0.43 to 1) (-0.59 to 1) (-0.59 to 1)
Median 40.5 29.0 36.5 Median 0.62 0.27 0.52
Mean 38.8 29.1 35.5 Mean 0.55 0.32 0.44
SD 8.5 9.9 8.5 SD 0.34 0.37 0.39
Effect Size* - 1.14 0.39 Effect Size* - 0.64 0.30
t-test† - < 0.001 0.064 t-test† - < 0.001 0.012
(c) EQ VAS (d) ICECAP-O
n 226 146 76 n 113 59 29
Range (0 to 100) (5 to 100) (10 to 100) Range (0.25 to 1) (0.00 to 1) (0.25 to 1)
Median 70.0 65.0 70.0 Median 0.82 0.76 0.88
Mean 65.2 62.6 65.4 Mean 0.79 0.73 0.83
SD 21.5 22.0 20.2 SD 0.16 0.22 0.17
Effect Size - 0.12 -0.01 Effect Size† - 0.39 -0.24
t-test - 0.363 0.999 t-test‡ - 0.018 0.355
* Effect size, change in mean from baseline/baseline standard deviation





















Receiver operating characteristic (ROC) curves for WHiT EQ-5D at
six weeks and subsequent death and revision within 12 months;
data (solid) and smoothed curves (dashed)
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for death was 0.72 (95% CI; 0.57, 0.85 for 2000 bootstrap
replicates) and the area under the ROC curve for revision
was 0.49 (95% CI; 0.38, 0.62). The AUC measures dis-
crimination, that is, the ability of EQ-5D to classify correctly
those who will die or be revised within 12 months; a value
of 0.5 indicates no predictive value. Therefore, EQ-5D is
not predictive of revision, but is moderately good predic-
tor of death within 12 months.
The estimated effect size in the WHiTE Study decreased
from a medium to a small level during follow-up for
EQ-5D, consistent with the change in mean scores. There
was an analogous decrease in effect sizes, from large to
small, from four weeks to four months for OHS. EQ-VAS
proved to be unresponsive to change from baseline and
ICECAP-O was moderately responsive at four weeks only. 
Proxy reported EQ-5D. For those participants with cog-
nitive impairment (nominally referred to here as
‘demented’) EQ-5D was reported by an appropriate
proxy. Temporal trends in scores for demented and non-
demented groups, shown in Figure 2, were similar with
scores being lower overall for the latter than the former
group. Estimated effect sizes at the four week assessment
for the two groups were 0.85 and 0.58 and of approxi-
mately the same magnitude as those observed for the full
population (Table IV).
Comparison between EQ-5D and other instruments.
Pair-wise correlations for EQ-5D, OHS and ICECAP-O at
baseline, four weeks and four months (Table V) showed
that there were significant strong positive correlations,
> 0.7, between EQ-5D and OHS at all occasions. Correla-
tions between EQ-5D and ICECAP-O, and between
ICECAP-O and OHS were also all significant, although
smaller than between EQ-5D and OHS, at baseline and four
weeks. The correlations between EQ-5D and ICECAP-O,
and between ICECAP-O and OHS failed to reach
significance due to the paucity of available data at this
occasion. This is apparent in the scatter-plots between
pairs of outcome measures at each occasion (Figure 3). 
Item-to-item correlations between EQ-5D and OHS at
four weeks showed a strong correlation (0.72; 95%
bootstrapped CI 0.51 to 0.85) between the EQ-5D Self
Care domain and OHS item 2 (Have you had any trouble
washing and drying yourself because of your hip?). There
were similar strong associations between the EQ-5D
‘Mobility’, ‘Usual Activities’ and ‘Pain’ domains and those
aspects of the OHS that were relevant to these construct
(e.g. walking or climbing stairs for ‘Mobility’). There were
generally many fewer significant associations between
the EQ-5D ‘Anxiety’ domain and OHS questionnaire
items, consistent with what one might expect for this
construct that does not feature explicitly in the OHS.
Recall of pre-fracture status. The mean baseline EQ-5D
scores were 0.66 (95% CI; 0.61 to 0.71) and 0.55
(95% CI; 0.50 to 0.59) for the WHiT and WHiTE studies
respectively. A more informative categorisation for the
WHiTE study gave means of 0.39 (95% CI; 0.33 to 0.45)
and 0.66 (95% CI; 0.60 to 0.71) for the demented and
non-demented groups. The UK normative data20,21
derived from face-to-face interviews with randomly
selected individuals from England, Scotland and Wales,
suggest a mean EQ-5D score of approximately 0.680 for
the 80+ age group, based on tabulated data that consists
of marginal proportional splits by level and EQ-5D cate-
gory. This is close to our reported values for both WHiT
and WHiTE, taking the non-demented group as a more
realistic point of comparison for the latter group, and pro-
vides strong evidence for the veracity (reliability) of retro-
spective assessments of EQ-5D in this population.
Discussion
This study compared the measurement properties of
three types of patient-reported outcome measure in
Table V. Pair-wise Pearson correlation coefficients between outcome measures for WHiTE, with 95% confidence
intervals from 1000 bootstrap replicates. 4 w, four weeks; 4 m, four months
Pair-wise terms* Baseline 4 w 4 m
EQ-5D OHS 0.74 (0.66 to 0.82) 0.77 (0.63 to 0.80) 0.70 (0.57 to 0.82)
EQ-5D ICECAP-O 0.34 (0.19 to 0.49) 0.62 (0.43 to 0.75) 0.47 (-0.07 to 0.76)
ICECAP-O OHS 0.38 (0.23 to 0.55) 0.54 (0.36 to 0.70) 0.37 (-0.17 to 0.76)


















Boxplots for WHiTE for EQ-5D at baseline, four weeks and four
months for demented and non-demented patients; symbols (●) and
bars show means and 95% confidence intervals
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patients with a fragility fracture of the hip. We found that
hip fracture has large effects on quality of life that can be
detected using a general HRQOL measure.
Furthermore, the general measure (EQ-5D) correlates
strongly with a hip specific PROM (OHS) and is almost as
responsive to changes over time. The measure of capability
in older people was not responsive to change in patients
with hip fracture. EQ-5D is also a moderately good predic-
tor of death at 12 months following hip fracture. Finally our
data suggests that EQ-5D scores can reasonably be col-
lected from proxies (relatives and carers) where partici-
pants are unable to complete the questions themselves.
EQ-5D is a global measure, and as such it is designed to
capture the complex and multifactorial aspects of a
patient’s health status. It is not a PROM for hip fracture
surgery specifically. However, it is not at all clear whether
a PROM specific to hip fracture could be developed in this
group of patients, who often have difficulty articulating
which aspects of their health experience relate to the hip
fracture and which relate to other conditions.
Given that no specific measure exists and is unlikely to
be developed, it is surprising that the evidence for avail-
able outcome measures in this elderly population is
poor.6 However, the measurement properties of EQ-5D
have been widely studied more generally.22-24 EQ-5D also
facilitates the generation of health utility. Despite its gen-
eral health status heritage, EQ-5D covers the domains of
health which patients consider important in their
EQ-5D score EQ-5D score
EQ-5D scoreEQ-5D score
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Fig. 3
Scatter-plots between pair-wise combinations of EQ-5D, Oxford Hip Score (OHS) and ICECAP-O from WHiTE at baseline (top row), four weeks (mid-
dle row) and four months (bottom row); solid lines show linear regression fit, with 95% prediction intervals shown as dashed lines
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recovery following hip fracture: (i) mobility, (ii) self-care,
(iii) usual activities, (iv) pain and discomfort and (v) anxi-
ety and depression.7
The OHS has been shown previously to map accurately
onto the EQ-5D utility index;25 with a correlation and
regression coefficient consistent with the analysis reported
here. The good responsiveness properties of EQ-5D
reported here confirms analyses reported elsewhere for
elderly patients with hip fractures.26 Up to 40% of
patients with a hip fracture have permanent cognitive
impairment.3 When comparing patients without cogni-
tive impairment, who provided their own EQ-5D score,
and proxy scores for those with cognitive impairment,
EQ-5D proved similarly responsive in both groups and
supports evidence reported elsewhere for proxy comple-
tion of EQ-5D in patients with dementia.27
The main limitation of this study is the fact that all of
the data were collected in one trauma centre. However,
the baseline characteristics of the patients were very sim-
ilar to those recorded in the NHFD report,3 suggesting
that the patients were representative of patients with hip
fracture throughout the UK.
In contrast with other areas of healthcare, it seems that
a general-HRQOL tool such as EQ-5D could be used to
measure outcome for patients recovering from hip frac-
ture; including those with cognitive impairment. Further
research is required to see if it is feasible to collect EQ-5D
scores in other centres around the country and, more
importantly, whether the collection of patient-reported
outcomes can be used to improve the design and delivery
of healthcare for this vitally important group of patients.
Supplementary material
Three tables and six figures showing correlations
and distributions at various time points are available
alongside this article at www.bjr.boneandjoint.org.uk
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